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ABSTRACT
Objectives: To evaluate clinical response by baseline
disease duration using 2-year data from the AMPLE
trial.
Methods: Patients were randomised to subcutaneous
abatacept 125 mg weekly or adalimumab 40 mg bi-
weekly, with background methotrexate. As part of a post
hoc analysis, the achievement of validated definitions of
remission (Clinical Disease Activity Index (CDAI) ≤2.8,
Simplified Disease Activity Index (SDAI) ≤3.3, Routine
Assessment of Patient Index Data 3 (RAPID3) ≤3.0,
Boolean score ≤1), low disease activity (CDAI <10,
SDAI <11, RAPID3 ≤6.0), Health Assessment
Questionnaire-Disability Index response and American
College of Rheumatology responses were evaluated by
baseline disease duration (≤6 vs >6 months). Disease
Activity Score 28 (C-reactive protein) <2.6 or ≤3.2 and
radiographic non-progression in patients achieving
remission were also evaluated.
Results: A total of 646 patients were randomised and
treated (abatacept, n=318; adalimumab, n=328). In both
treatment groups, comparable responses were achieved
in patients with early rheumatoid arthritis (≤6 months)
and in those with later disease (>6 months) across
multiple clinical measures.
Conclusions: Abatacept or adalimumab with
background methotrexate were associated with similar
onset and sustainability of response over 2 years.
Patients treated early or later in the disease course
achieved comparable clinical responses.
Trial registration number: NCT00929864, Post-
results.
INTRODUCTION
Several clinical outcome measures exist to
measure disease activity in patients with
rheumatoid arthritis (RA). Although not vali-
dated for remission or low disease activity
(LDA), one often-used measure is the Disease
Activity Score 28 (C-reactive protein; DAS28
(CRP)).1–3 A second index—the Clinical
Disease Activity Index (CDAI)—has been
widely used to measure remission (≤2.8) and
LDA (≤10.0).4–6 A third index—the Routine
Assessment of Patient Index Data 3 (RAPID3)
—correlates with DAS28 (CRP) and CDAI.7
Finally, the American College of
Rheumatology (ACR) and the European
League Against Rheumatism (EULAR) have
established criteria that employ an index-
Key messages
What is already known about this subject?
▸ Patients with longer disease duration have been
shown to respond less well to treatment with
conventional synthetic disease-modifying anti-
rheumatic drugs (DMARDs) than patients with
rheumatoid arthritis of shorter duration.
What does this study add?
▸ This study demonstrates that treatment with
abatacept or adalimumab and background
methotrexate, whether earlier or later in the
course of disease, leads to comparable clinical
benefits, irrespective of the criteria used to
assess disease activity.
▸ Data from this post hoc analysis suggest that the
effect of disease duration on treatment response
may be minimal if patients are treated with an
effective biological DMARD and patients can
achieve comparable responses whether treated
early in the course of the disease or later.
How might this impact on clinical practice?
▸ When measuring treatment response in clinical
practice, the choice of disease activity measures
to be used and their interpretations presents
numerous complexities.
▸ The use of multiple measures of clinical remis-
sion and low disease activity in this unique
comparative data set from the Abatacept versus
adaliMumab comParison in bioLogic-naïvE
rheumatoid arthritis subjects with background
methotrexate (AMPLE) study confirms their
utility and consistency for agents with different
mechanisms.
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based definition, Simplified Disease Activity Index
(SDAI) ≤3.3, or a Boolean definition ≤1,6 and have
recommended that either definition should be selected
as an outcome measure defining remission in RA clinical
trials.6
Several studies of patients on biological disease-
modifying antirheumatic drugs (bDMARDs) have shown
long-term improvements in functional and radiographic
outcomes following treatment,8–11 and it has been
demonstrated that early initiation of DMARDs improves
clinical and structural outcomes.12–14
Abatacept versus adaliMumab comParison in bioLogic-
naïvE rheumatoid arthritis subjects with background
methotrexate (AMPLE) was the first head-to-head study
powered to compare bDMARDs with different mechan-
isms of action on a background of methotrexate (MTX)
in patients with RA who were naïve to bDMARD therapy
and in whom MTX therapy had not provided adequate
response. In 1-year and 2-year analyses, the efficacy and
safety of abatacept and adalimumab were comparable.8 9
Here, we summarise clinical response by baseline disease
duration, using 2-year data from the AMPLE trial.
METHODS
Study design
The trial design for AMPLE (NCT00929864) has been
described previously.8 Patients were randomised to subcuta-
neous (SC) abatacept (Bristol-Myers Squibb, Princeton,
New Jersey, USA) 125 mg weekly or SC adalimumab
(Abbott Laboratories, North Chicago, Illinois, USA) 40 mg
bi-weekly, in combination with a stable dose of MTX. The
maximum disease duration for study entry was 5 years. 8
Assessments
In a post hoc analysis, patients in the intent-to-treat
population were grouped according to disease duration
at baseline (≤6 (early) vs >6 months (later disease) for
each treatment15). Rates of remission and LDA were
assessed using several disease activity criteria. DAS28
(CRP) ‘remission’ was defined in the protocol as <2.6
and ‘LDA’ as ≤3.2 (tender joint counts (TJCs) and
swollen joint counts (SJCs) out of 28 joints, CRP and
patient global assessment (100 mm visual analogue scale
(VAS)).6 CDAI remission was defined as ≤2.8 and LDA
<10.0 (TJC and SJC (66/68 joints), patient and physician
global assessment (0–10 VAS)).4 6 SDAI remission was
defined as ≤3.3 and LDA ≤11 (TJC and SJC, CRP,
patient and physician global assessment (0–10 VAS)).6
RAPID3 remission was defined as ≤3.0 and LDA ≤6.0
(Health Assessment Questionnaire-Disability Index
(HAQ-DI), patient pain score and patient global assess-
ment (both 100 mm VAS)). Boolean remission was
assessed (TJC and SJC, CRP and patient global assess-
ment), but LDA was not determined by the Boolean def-
inition.6 Physical function was assessed using the
HAQ-DI, and a clinically meaningful HAQ-DI response
was defined as an improvement of 0.3 units from
baseline.16 17
Plain radiographs of hands and feet were taken at
baseline, years 1 and 2, and scored using the modified
Sharp/van der Heijde scoring system (see online
supplementary material).18
The proportion of patients in each group achieving
an ACR 20%, 50% and 70% improvement response rate
(ACR20/50/70) was assessed at 2 years. 19
Table 1 Baseline demographics and clinical characteristics (intent-to-treat population)
Total population ≤6 months’ disease duration >6 months’ disease duration
Characteristic
SC
abatacept
+MTX
(n=318)
SC
adalimumab
+MTX
(n=328)
SC
abatacept
+MTX
(n=71)
SC
adalimumab
+MTX
(n=70)
SC
abatacept
+MTX
(n=247)
SC
adalimumab
+MTX
(n=258)
Patients completing the
study at year 2, n (%)
252 (79.2) 245 (74.7) 54 (76.1) 49 (70.0) 198 (80.2) 196 (76.0)
Median (minimum,
maximum) age, years
52 (19, 83) 52 (19, 85) 50 (19, 80) 52 (22, 75) 53 (21, 83) 52 (19, 85)
Female, n (%) 259 (81.4) 270 (82.3) 59 (83.1) 51 (72.9) 200 (81.0) 219 (84.9)
White, n (%) 257 (80.8) 256 (78.0) 60 (84.5) 57 (81.4) 197 (79.8) 199 (77.1)
Geographic region, n (%)
North America 230 (72.3) 235 (71.6) 67 (94.4) 63 (90.0) 163 (66.0) 172 (66.7)
South America 88 (27.7) 93 (28.4) 4 (5.6) 7 (10.0) 84 (34.0) 86 (33.3)
Mean (SD) disease
duration, years
1.9 (1.4) 1.8 (1.4) 0.3 (0.1) 0.3 (0.1) 2.4 (1.3) 2.2 (1.3)
Median HAQ-DI 1.5 1.5 1.5 1.5 1.5 1.4
Median DAS28 (CRP) 5.5 5.5 5.5 5.7 5.6 5.4
Median CDAI 36.2 36.5 34.4 38.0 36.2 39.2
Median SDAI 38.1 37.6 37.0 36.3 38.3 37.4
CDAI, Clinical Disease Activity Index; DAS28 (CRP), Disease Activity Score 28 (C-reactive protein); HAQ-DI, Health Assessment
Questionnaire-Disability Index; MTX, methotrexate; SC, subcutaneous; SDAI, Simplified Disease Activity Index.
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Statistical analysis
In all patients who had completed year 2 (day 729) of
the study, individual measures of remission/LDA (CDAI,
SDAI, RAPID3, Boolean (remission only)) were calcu-
lated using post hoc analyses of as-observed data. Mean
rates of ACR20/50/70 response, mean remission/LDA
(CDAI, SDAI, RAPID3, Boolean (remission only)) and
HAQ-DI were calculated and compared by disease dur-
ation subgroup (≤6 and >6 months) for each treatment
(see online supplementary materials). For all mean
response rates, 95% CIs were calculated.
RESULTS
Patient population
Baseline demographics and clinical characteristics of the
total population, and by disease duration, are shown in
table 1. A total of 646 patients were randomised and
treated with background MTX: 318 in the abatacept
group and 328 in the adalimumab group. In total,
79.2% (252/318) of patients in the SC abatacept group
and 74.7% (245/328) of patients in the adalimumab
group completed year 2.9 In patients receiving
abatacept, 22.3% (71/318) had ≤6 months’ disease dur-
ation at baseline and 77.7% (247/318) had >6 months’
disease duration; 76.1% (54/71) of patients with
≤6 months’ disease duration and 80.2% (198/247) with
>6 months’ disease duration completed year 2. The dis-
tribution of disease duration at baseline and those who
completed year 2 for the adalimumab-treated patients
was comparable to that of abatacept-treated patients
(table 1).
Efficacy
Overall, in patients achieving remission or LDA at year
1, most maintained remission at 2 years irrespective of
the definition used. The rates of sustained remission
and DAS28 (CRP) <2.6 and ≤3.2 were comparable
between the abatacept and adalimumab treatment arms
(see online supplementary table S1). More than 85% of
patients who achieved remission or LDA at year 2, irre-
spective of the definition used, had radiographic non-
progression at year 2 (see online supplementary figures
S1–4). There was a high correlation with improvements
in physical function in patients who had achieved remis-
sion or LDA at year 2, irrespective of the criteria used
Figure 1 Proportion of patients with SDAI LDA or remission with disease duration at baseline of (A) ≤6 months or (B)
>6 months; CDAI LDA or remission with disease duration at baseline of (C) ≤6 months or (D) >6 months. (A, B) Remission
defined as SDAI response ≤3.3. LDA defined as SDAI response ≤11.0. (C, D) Remission defined as CDAI response ≤2.8. LDA
defined as CDAI response ≤10.0. Number of randomised and treated patients with disease duration ≤6 months: SC abatacept,
n=71; SC adalimumab, n=70. Number of randomised and treated patients with disease duration >6 months: SC abatacept,
n=247; SC adalimumab, n=258. an=62 at day 365, n=54 at day 729. bn=54 at day 365, n=49 at day 729. cn=62 at day 365, n=54
at day 729. dn=54 at day 365, n=49 at day 729. en=213 at day 365, n=196 at day 729. fn=213 at day 365, n=194 at day 729.
gn=213 at day 365, n=196 at day 729. hn=213 at day 365, n=194 at day 729. in=62 at day 365, n=54 at day 729. jn=54 at day
365, n=49 at day 729. kn=62 at day 365, n=54 at day 729. ln=54 at day 365, n=49 at day 729. mn=215 at day 365, n=196 at day
729. nn=214 at day 365, n=195 at day 729. on=215 at day 365, n=196 at day 729. pn=214 at day 365, n=195 at day 729. All error
bars represent 95% CIs. CDAI, Clinical Disease Activity Index; LDA, low disease activity; SC, subcutaneous; SDAI, Simplified
Disease Activity Index.
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for remission and LDA (see online supplementary
figure S5).
In patients with ≤6 months’ disease duration, out-
comes for the abatacept and adalimumab groups were
comparable, regardless of LDA or remission definition
(figure 1; see online supplementary figure S6).
Additionally, comparable proportions of patients in both
treatment groups achieved ACR20, 50 and 70 response
rates, regardless of their disease duration at baseline
(see online supplementary figure S7). In the
≤6 months’ disease duration group, proportions of
patients receiving abatacept or adalimumab who had
achieved ACR responses at year 2 were 72.2% and 73.5%
for ACR20, 55.6% and 51.0% for ACR50, and 37.0% and
28.6% for ACR70, respectively. The proportions of
patients with >6 months’ disease duration who had
achieved ACR responses were 75.4% and 80.3% for
ACR20, 56.3% and 63.6% for ACR50, and 39.7% and
40.9% for ACR70, respectively.
The proportions of patients who achieved clinically
meaningful HAQ-DI responses over time, by disease dur-
ation at baseline, are shown in figure 2. For patients with
≤6 months’ disease duration, 52.1% on SC abatacept
and 41.4% on adalimumab achieved HAQ-DI responses
at year 2, while for those with >6 months’ disease dur-
ation, 54.7% and 50.8% achieved HAQ-DI responses.
DISCUSSION
Biological-naïve patients treated with abatacept or adali-
mumab on background MTX achieved comparable
responses over 2 years in terms of onset and sustainabil-
ity of LDA and remission, HAQ-DI response and inhib-
ition of radiographic progression, irrespective of the
Figure 2 Proportion of patients
with HAQ-DI response, by
disease duration (ITT population):
(A) ≤6 months or (B) >6 months.
*HAQ-DI response defined as an
improvement of ≥3 units from
baseline. an=71 at day 365, n=71
at day 729. bn=70 at day 365,
n=70 at day 729. cn=247 at day
365, n=247 at day 729. dn=258 at
day 365, n=258 at day 729. Error
bars represent 95% CIs. HAQ-DI,
Health Assessment
Questionnaire-Disability Index;
ITT, intent-to-treat; SC,
subcutaneous.
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criteria used to assess disease activity. Disease duration
did not affect clinical response (reductions in disease
activity as assessed by SDAI, CDAI, RAPID3, Boolean
remission and HAQ-DI). In this group of patients who
had a maximum disease duration of 5 years at study
entry, abatacept-treated and adalimumab-treated patients
with early RA (≤6 months’ duration) achieved compar-
able responses to those with later disease (>6 months’
duration) across a range of clinical measures.
Patients who achieved remission according to stringent
criteria (SDAI, Boolean) were more likely to be radio-
graphic non-progressors and achieve clinically meaning-
ful improvements in physical function than those who
achieved LDA or DAS (CRP) ≤3.2. Patients achieving
CDAI-defined remission displayed similar radiographic
outcomes over 2 years to those achieving SDAI remission
(see online materials).
Patients with longer disease duration have been shown
to respond less well to treatment with conventional syn-
thetic DMARDs than patients with RA of shorter dur-
ation.12–14 20 A meta-analysis of about 1400 patients with
RA from 14 randomised trials using ACR20 response
rates identified shorter (≤1 year) disease duration at the
start of treatment to be one of the strongest predictors
of response to conventional synthetic DMARD therapy.12
However, data from the current post hoc analysis suggest
that the effect of disease duration on treatment response
may be minimal if patients are treated with an effective
bDMARD; patients can achieve comparable responses
whether treated early in the course of the disease
(defined as ≤6 months in this study based on ACR
criteria) or later (>6 months).15 The disparities between
the results of the present and previous studies may be
linked to changes in more efficacious treatment options
and differences in cut-offs used to separate disease dur-
ation cohorts.
When measuring treatment response, either in clinical
studies or clinical practice, the choice of disease activity
measures to be used and their interpretations presents
numerous complexities. The use of multiple measures
of clinical remission and LDA in this unique compara-
tive AMPLE data set confirms their utility and consist-
ency for agents with different mechanisms.
There are some limitations to the present study. The
analyses presented here are post hoc, and additional
prospective studies are needed to confirm these results.
The selection of DAS28 (CRP) as a measure of disease
activity is also a limitation. The criteria of DAS28 (CRP)
<2.6 and ≤3.2 were defined prior to the recent guidance
from the US Food and Drug Administration, which
states that DAS28 (CRP) <2.6 is a measure of LDA
rather than remission.2 DAS28 (CRP) also shows no cor-
relation with DAS28 (erythrocyte sedimentation rate),
and neither corresponds well with CDAI or SDAI.1 We
did, however, utilise defined criteria of remission (CDAI,
SDAI, Boolean, RAPID3) in this post hoc analysis and
the results are consistent with these validated
measurements.
This study demonstrates that treatment with abatacept
or adalimumab and background MTX, whether earlier
or later in the course of disease, leads to comparable
clinical benefits at least up to 5 years’ disease duration,
irrespective of the criteria used to assess disease activity.
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